BMS-986365 for Prostate Cancer
(rechARge Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.
Who Is on the Research Team?
Bristol-Myers Squibb
Principal Investigator
Bristol-Myers Squibb
Are You a Good Fit for This Trial?
This trial is for men with metastatic castration-resistant prostate cancer. Participants should not have had certain previous treatments and must be healthy enough to receive new therapy. Specific criteria will determine eligibility.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment Part 1
Participants are randomized to one of the two BMS-986365 dose levels or to the active comparator arm
Treatment Part 2
Participants are randomized between BMS-986365 selected dose or to the active comparator arm
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- BMS-986365
Find a Clinic Near You
Who Is Running the Clinical Trial?
Celgene
Lead Sponsor
Jay Backstrom
Celgene
Chief Medical Officer since 2016
MD
Mark Alles
Celgene
Chief Executive Officer since 2016
Bachelor's degree from Lock Haven University of Pennsylvania